Skip to content

Beat COVID-19 - Observational Trial

A Virtual Observational Protocol to Gain Longitudinal Data in Participants to Help Understand COVID-19 Spread and Disease Progression

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04337762
Acronym
JUPITER
Enrollment
100000
Registered
2020-04-08
Start date
2020-04-06
Completion date
2021-07-31
Last updated
2020-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

JUPITER is an observational study protocol that aims to understand factors that can help prevent/mitigate the spread of COVID-19 and understand factors that help reduce disease progression in patients with COVID-19. We aim to accomplish this by obtaining self-reported historical and longitudinal data from study participants.

Detailed description

This is an observational study that will electronically collect self-reported participant data in a database that follows HIPAA security requirements for those with a clinically confirmed case of COVID-19 or those who have had exposure to COVID-19. The aim of this study is to gather a large, diverse dataset from a large population of participants in order to gather longitudinal observational data on what health practices participants are practicing and what, if any, benefits these practices may be providing the participants. Data for this study will be gathered via self-reporting from participants who wish to participate in the fight against COVID-19. This will include getting a baseline of each participant's health and then monitor their health over time while looking at how their symptoms are progressing or regressing. The JUPITER study may also seek historical data from patients who have recovered from COVID-19. The JUPITER dataset may be shared (in accordance with applicable state, federal, and local laws) so that others may utilize the data from the dataset for further analysis to determine relevant trends in the data and in turn hopefully use these trends to determine potential treatment protocols or lifestyle recommendations to help prevent COVID-19 spread and reduce hospitalization rates, as well as to understand how certain factors may aide in the COVID-19 disease progression.

Interventions

None listed

Sponsors

Beat COVID LLC
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 110 Years

Inclusion criteria

1. Adults residing in the United States aged 18 years or older proficient in understanding and reading the English language who wish to participate in the fight against COVID-19 by providing self-reported health information. 2. Ability to complete electronic informed consent process. 3. Ability to use the internet and check email regularly. 4. Consent to provide a HIPAA waiver of health information to share protected health information.

Exclusion criteria

1\. Inability to provide regular updates to their health status when contacted by the BEAT COVID study personnel via email or SMS.

Design outcomes

Primary

MeasureTime frameDescription
Health Outcomes1 yearPatterns of data will be mined to understand risks for hospitalization and disease progression associated with COVID-19

Countries

United States

Contacts

Primary ContactRama Jager, M.D.
rjager@beatcovidtrial.com(708) 620-4608
Backup ContactHollis Ledbetter
hledbetter@beatcovidtrial.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026